Obsidian Therapeutics Announces Positive Clinical Data in Advanced Melanoma Study

Obsidian Therapeutics has announced initial Phase 1 safety and efficacy results from its ongoing Agni-01 study of OBX-115, a novel engineered autologous TIL cell therapy enhanced with pharmacologically controlled IL15 (mbIL15). The therapy is being evaluated in patients with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma. 

Learn more